The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Resistance to Somatostatin Analogs in Acromegaly
Abstract
Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia. Generally, the response to SA takes into account both control of GH and IGF-I excess, with consequent improvement of clinical symptoms directly related to GH and IGF-I excess, and tumor shrinkage. This latter effect is more prominent in the patients treated first-line and bearing large macroadenomas, but it is also observed in patients with microadenomas, even with little clinical implication. Predictors of response are patients' gender, age, initial GH and IGF-I levels, and tumor mass, as well as adequate expression of somatostatin receptor types 2 and 5, those with the highest affinity for octreotide and lanreotide. Only sporadic cases of somatostatin receptor gene mutation or impaired signaling pathways have been described in GH-secreting tumors so far. The response to SA also depends on treatment duration and dosage of the drug used, so that a definition of resistance based on short-term treatments using low doses of long-acting SA is limited. Current data suggest that response to these drugs is better analyzed taking together biochemical and tumoral effects because only the absence of both responses might be considered as a poor response or resistance. This latter evidence seems to occur in 25% of treated patients after 12 months of currently available long-acting SA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Self-citationMelmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Reichlin, S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312153092406 · Cited by 1,044
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., & Patel, Y. C. (2000) · Science · doi:10.1126/science.288.5463.154 · Cited by 888
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Self-citationFactors Influencing Mortality in Acromegaly
Holdaway, I. M., Rajasoorya, R. C., & Gamble, G. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031199 · Cited by 651
Cited by
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationGadelha, M. R., Bronstein, M. D., Brue, T., Coculescu, M., Fleseriu, M., Guitelman, M., Pronin, V., Raverot, G., Shimon, I., Lievre, K. K., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70169-x · Cited by 396
Self-citationColao, A., Grasso, L. F. S., Giustina, A., Melmed, S., Chanson, P., Pereira, A. M., & Pivonello, R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0071-6 · Cited by 396
Self-citationA consensus on the diagnosis and treatment of acromegaly complications
Melmed, S., Casanueva, F. F., Klibanski, A., Bronstein, M. D., Chanson, P., Lamberts, S. W., Strasburger, C. J., Wass, J. A. H., & Giustina, A. (2013) · Pituitary · doi:10.1007/s11102-012-0420-x · Cited by 325
Aggressive pituitary adenomas—diagnosis and emerging treatments
Di Ieva, A., Rotondo, F., Syro, L. V., Cusimano, M. D., & Kovacs, K. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.64 · Cited by 318
Acromegaly: pathogenesis, diagnosis, and management
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V., & Melmed, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00244-3 · Cited by 279
Metadata
- Authors
- Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2010-12-01
- Volume
- 32
- Issue
- 2
- Pages
- 247-271
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2158629056
- Cited by
- 257
- References
- 130
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.